Maryanne Makredes Senna, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alopecia | 44 | 2024 | 382 | 16.050 |
Why?
|
Alopecia Areata | 21 | 2024 | 107 | 9.630 |
Why?
|
Lichen Planus | 6 | 2023 | 57 | 4.510 |
Why?
|
Scalp | 11 | 2023 | 380 | 4.140 |
Why?
|
Hydroxychloroquine | 5 | 2023 | 412 | 3.220 |
Why?
|
Cicatrix | 11 | 2024 | 764 | 2.810 |
Why?
|
Minoxidil | 3 | 2023 | 33 | 2.440 |
Why?
|
Dermatitis | 3 | 2022 | 197 | 2.200 |
Why?
|
Cosmetics | 3 | 2022 | 97 | 2.120 |
Why?
|
Hair | 8 | 2023 | 483 | 1.800 |
Why?
|
Hair Preparations | 3 | 2022 | 32 | 1.690 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2022 | 107 | 1.390 |
Why?
|
Spironolactone | 2 | 2023 | 382 | 1.260 |
Why?
|
Allergens | 3 | 2022 | 1320 | 1.030 |
Why?
|
Dermatitis, Atopic | 3 | 2021 | 654 | 1.020 |
Why?
|
Skin Diseases | 3 | 2023 | 1065 | 0.920 |
Why?
|
Psoriasis | 3 | 2021 | 898 | 0.920 |
Why?
|
Hair Follicle | 3 | 2020 | 209 | 0.910 |
Why?
|
Finasteride | 2 | 2023 | 90 | 0.870 |
Why?
|
Azetidines | 1 | 2024 | 142 | 0.870 |
Why?
|
Vitamin D Deficiency | 2 | 2022 | 1343 | 0.850 |
Why?
|
Emollients | 1 | 2022 | 34 | 0.830 |
Why?
|
Sex Reassignment Procedures | 2 | 2019 | 50 | 0.830 |
Why?
|
Dermatitis, Allergic Contact | 2 | 2022 | 104 | 0.830 |
Why?
|
Hair Diseases | 1 | 2021 | 74 | 0.760 |
Why?
|
Hyperkalemia | 1 | 2023 | 218 | 0.760 |
Why?
|
Subcutaneous Tissue | 1 | 2021 | 135 | 0.750 |
Why?
|
Purines | 1 | 2024 | 594 | 0.740 |
Why?
|
Insurance | 1 | 2021 | 111 | 0.710 |
Why?
|
Hypertrichosis | 1 | 2019 | 25 | 0.710 |
Why?
|
Carcinoid Tumor | 1 | 2021 | 235 | 0.700 |
Why?
|
Cryotherapy | 2 | 2022 | 155 | 0.680 |
Why?
|
Hair Removal | 1 | 2019 | 42 | 0.680 |
Why?
|
Interleukin-13 | 1 | 2020 | 389 | 0.650 |
Why?
|
Hypothermia, Induced | 2 | 2022 | 752 | 0.650 |
Why?
|
Nail Diseases | 1 | 2018 | 51 | 0.640 |
Why?
|
Transsexualism | 1 | 2021 | 178 | 0.620 |
Why?
|
Skin Diseases, Genetic | 1 | 2018 | 40 | 0.610 |
Why?
|
Facial Dermatoses | 1 | 2018 | 87 | 0.610 |
Why?
|
Marketing | 1 | 2019 | 212 | 0.580 |
Why?
|
Interleukin-4 | 1 | 2020 | 1147 | 0.580 |
Why?
|
Graft vs Host Disease | 2 | 2019 | 2957 | 0.560 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2020 | 370 | 0.550 |
Why?
|
Dermatologic Agents | 1 | 2019 | 278 | 0.540 |
Why?
|
Humans | 76 | 2024 | 744343 | 0.540 |
Why?
|
Life Change Events | 1 | 2021 | 938 | 0.530 |
Why?
|
Acne Vulgaris | 1 | 2020 | 302 | 0.530 |
Why?
|
Ossification, Heterotopic | 1 | 2018 | 239 | 0.520 |
Why?
|
Sulfonamides | 1 | 2024 | 1938 | 0.480 |
Why?
|
Bone Diseases, Metabolic | 1 | 2018 | 417 | 0.480 |
Why?
|
Hormone Replacement Therapy | 1 | 2019 | 745 | 0.460 |
Why?
|
Food Hypersensitivity | 1 | 2020 | 622 | 0.460 |
Why?
|
Anxiety | 3 | 2022 | 4297 | 0.440 |
Why?
|
Attitude to Health | 1 | 2021 | 2052 | 0.400 |
Why?
|
Biological Products | 1 | 2021 | 860 | 0.400 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1377 | 0.390 |
Why?
|
Female | 35 | 2024 | 380194 | 0.390 |
Why?
|
Fibrosis | 3 | 2023 | 2029 | 0.380 |
Why?
|
Photography | 3 | 2022 | 520 | 0.360 |
Why?
|
Administration, Topical | 2 | 2023 | 690 | 0.350 |
Why?
|
Skin Neoplasms | 5 | 2021 | 5686 | 0.340 |
Why?
|
Burns | 1 | 2020 | 1815 | 0.330 |
Why?
|
Cross-Sectional Studies | 8 | 2022 | 25043 | 0.310 |
Why?
|
Insurance Coverage | 1 | 2019 | 1901 | 0.310 |
Why?
|
Quality of Life | 6 | 2024 | 12804 | 0.310 |
Why?
|
Patient Satisfaction | 1 | 2020 | 3396 | 0.300 |
Why?
|
Health Status Disparities | 1 | 2019 | 1797 | 0.300 |
Why?
|
Gender Identity | 2 | 2021 | 688 | 0.270 |
Why?
|
Kidney Transplantation | 1 | 2021 | 4251 | 0.260 |
Why?
|
Perception | 2 | 2022 | 1198 | 0.250 |
Why?
|
Irritants | 1 | 2023 | 44 | 0.240 |
Why?
|
Male | 22 | 2023 | 350118 | 0.240 |
Why?
|
Leprosy, Borderline | 1 | 2013 | 4 | 0.230 |
Why?
|
Tinea Versicolor | 1 | 2013 | 8 | 0.230 |
Why?
|
Leprosy, Lepromatous | 1 | 2013 | 23 | 0.230 |
Why?
|
Adult | 16 | 2024 | 214055 | 0.230 |
Why?
|
Face | 2 | 2019 | 994 | 0.220 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5137 | 0.210 |
Why?
|
Severity of Illness Index | 6 | 2021 | 15540 | 0.200 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.200 |
Why?
|
Eyelashes | 1 | 2021 | 16 | 0.200 |
Why?
|
Young Adult | 9 | 2021 | 56430 | 0.190 |
Why?
|
Eyebrows | 1 | 2020 | 28 | 0.190 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13695 | 0.190 |
Why?
|
Gallic Acid | 1 | 2020 | 24 | 0.180 |
Why?
|
Phototherapy | 1 | 2023 | 377 | 0.180 |
Why?
|
Hazardous Substances | 1 | 2021 | 149 | 0.180 |
Why?
|
Retrospective Studies | 9 | 2023 | 77449 | 0.180 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 841 | 0.180 |
Why?
|
Patch Tests | 1 | 2020 | 53 | 0.180 |
Why?
|
Iatrogenic Disease | 1 | 2023 | 547 | 0.180 |
Why?
|
Telecommunications | 1 | 2009 | 80 | 0.170 |
Why?
|
Tissue Transplantation | 1 | 2019 | 130 | 0.170 |
Why?
|
Atrophy | 1 | 2023 | 1583 | 0.170 |
Why?
|
Sunscreening Agents | 1 | 2009 | 132 | 0.170 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 45 | 0.160 |
Why?
|
Injections | 1 | 2022 | 840 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 11725 | 0.160 |
Why?
|
Steroids | 1 | 2023 | 930 | 0.160 |
Why?
|
Aged | 10 | 2021 | 163280 | 0.160 |
Why?
|
Middle Aged | 12 | 2020 | 213383 | 0.160 |
Why?
|
Biopsy | 2 | 2020 | 6756 | 0.150 |
Why?
|
Administration, Oral | 2 | 2023 | 3913 | 0.150 |
Why?
|
Autoimmune Diseases | 2 | 2018 | 2133 | 0.150 |
Why?
|
Lung Neoplasms | 1 | 2021 | 13102 | 0.140 |
Why?
|
Arthritis, Psoriatic | 1 | 2009 | 215 | 0.140 |
Why?
|
Reminder Systems | 1 | 2009 | 371 | 0.140 |
Why?
|
Cross-Over Studies | 1 | 2022 | 2029 | 0.140 |
Why?
|
Vitiligo | 1 | 2017 | 89 | 0.140 |
Why?
|
Consensus | 2 | 2024 | 2959 | 0.140 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1257 | 0.130 |
Why?
|
Comorbidity | 2 | 2021 | 10388 | 0.130 |
Why?
|
Complementary Therapies | 1 | 2019 | 486 | 0.130 |
Why?
|
Taxoids | 1 | 2019 | 666 | 0.130 |
Why?
|
Th2 Cells | 1 | 2020 | 1061 | 0.130 |
Why?
|
Embolism, Cholesterol | 1 | 2015 | 34 | 0.130 |
Why?
|
Breast Neoplasms | 2 | 2022 | 20822 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2020 | 1184 | 0.130 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2015 | 41 | 0.130 |
Why?
|
Transplantation, Autologous | 1 | 2019 | 2124 | 0.120 |
Why?
|
Cholesterol, LDL | 1 | 2024 | 2356 | 0.120 |
Why?
|
Simvastatin | 1 | 2017 | 360 | 0.120 |
Why?
|
Politics | 1 | 2010 | 791 | 0.120 |
Why?
|
Chronic Disease | 2 | 2019 | 9146 | 0.120 |
Why?
|
Pyrazoles | 1 | 2024 | 1972 | 0.110 |
Why?
|
Melanoma | 3 | 2021 | 5510 | 0.110 |
Why?
|
United States | 4 | 2022 | 69872 | 0.110 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2278 | 0.110 |
Why?
|
Piperidines | 1 | 2021 | 1602 | 0.110 |
Why?
|
Nevus | 1 | 2014 | 204 | 0.110 |
Why?
|
Drug Therapy, Combination | 1 | 2023 | 6489 | 0.110 |
Why?
|
Patients | 1 | 2019 | 900 | 0.110 |
Why?
|
Estrogens | 1 | 2019 | 1566 | 0.110 |
Why?
|
Suicidal Ideation | 1 | 2021 | 1248 | 0.110 |
Why?
|
Androgens | 1 | 2019 | 1281 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4933 | 0.100 |
Why?
|
Case-Control Studies | 2 | 2019 | 21746 | 0.100 |
Why?
|
Social Class | 1 | 2010 | 1999 | 0.100 |
Why?
|
Adolescent | 5 | 2021 | 85781 | 0.090 |
Why?
|
Prospective Studies | 4 | 2022 | 53288 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2018 | 1580 | 0.080 |
Why?
|
Patient Compliance | 1 | 2009 | 2684 | 0.080 |
Why?
|
Pilot Projects | 1 | 2022 | 8324 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 2942 | 0.080 |
Why?
|
Treatment Outcome | 5 | 2023 | 63114 | 0.080 |
Why?
|
Health Policy | 1 | 2021 | 2661 | 0.080 |
Why?
|
Self Report | 1 | 2019 | 3558 | 0.080 |
Why?
|
Health Care Costs | 1 | 2021 | 3209 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3022 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 9959 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2020 | 57776 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7785 | 0.060 |
Why?
|
Observer Variation | 2 | 2021 | 2593 | 0.060 |
Why?
|
Leprostatic Agents | 1 | 2013 | 14 | 0.060 |
Why?
|
Clofazimine | 1 | 2013 | 33 | 0.060 |
Why?
|
Dapsone | 1 | 2013 | 54 | 0.060 |
Why?
|
Mycobacterium leprae | 1 | 2013 | 94 | 0.060 |
Why?
|
Phenotype | 1 | 2020 | 16365 | 0.060 |
Why?
|
Hypesthesia | 1 | 2013 | 109 | 0.050 |
Why?
|
Histamine Antagonists | 1 | 2022 | 93 | 0.050 |
Why?
|
Minocycline | 1 | 2013 | 163 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 3255 | 0.050 |
Why?
|
Rifampin | 1 | 2013 | 315 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10262 | 0.050 |
Why?
|
Epidermis | 1 | 2023 | 528 | 0.050 |
Why?
|
Hong Kong | 1 | 2010 | 148 | 0.050 |
Why?
|
Cohort Studies | 2 | 2020 | 40561 | 0.050 |
Why?
|
Depression | 1 | 2019 | 7766 | 0.040 |
Why?
|
Delayed Diagnosis | 1 | 2013 | 441 | 0.040 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2021 | 214 | 0.040 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2018 | 91 | 0.040 |
Why?
|
Child, Preschool | 1 | 2021 | 41006 | 0.040 |
Why?
|
Morbidity | 1 | 2024 | 1769 | 0.040 |
Why?
|
Interleukin-15 | 1 | 2018 | 184 | 0.040 |
Why?
|
Body Surface Area | 1 | 2017 | 198 | 0.040 |
Why?
|
Risk Factors | 2 | 2020 | 72290 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2022 | 1683 | 0.030 |
Why?
|
Chemokine CXCL10 | 1 | 2017 | 304 | 0.030 |
Why?
|
California | 1 | 2009 | 1402 | 0.030 |
Why?
|
Giant Cell Arteritis | 1 | 2009 | 292 | 0.030 |
Why?
|
Pulmonary Fibrosis | 1 | 2009 | 530 | 0.030 |
Why?
|
Nevus, Spindle Cell | 1 | 2014 | 2 | 0.030 |
Why?
|
Keratinocytes | 1 | 2018 | 798 | 0.030 |
Why?
|
Epithelioid Cells | 1 | 2014 | 71 | 0.030 |
Why?
|
Probability | 1 | 2009 | 2505 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2009 | 2971 | 0.030 |
Why?
|
Reference Values | 1 | 2009 | 4982 | 0.030 |
Why?
|
Primary Prevention | 1 | 2009 | 1167 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2018 | 1366 | 0.030 |
Why?
|
Forecasting | 1 | 2010 | 2951 | 0.020 |
Why?
|
Melanocytes | 1 | 2014 | 515 | 0.020 |
Why?
|
Skin | 1 | 2023 | 4364 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2018 | 3206 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
Cytokines | 1 | 2023 | 7322 | 0.020 |
Why?
|
Medication Adherence | 1 | 2009 | 2063 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2018 | 2725 | 0.020 |
Why?
|
Colitis, Ulcerative | 1 | 2009 | 1912 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8340 | 0.020 |
Why?
|
Crohn Disease | 1 | 2009 | 2303 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2021 | 4245 | 0.020 |
Why?
|
Sex Factors | 1 | 2009 | 10397 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14722 | 0.020 |
Why?
|
Registries | 1 | 2010 | 8089 | 0.020 |
Why?
|
Databases, Factual | 1 | 2009 | 7729 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10638 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2017 | 12026 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18370 | 0.010 |
Why?
|
Prevalence | 1 | 2009 | 15226 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 19905 | 0.010 |
Why?
|
Incidence | 1 | 2010 | 20947 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11524 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10180 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18029 | 0.010 |
Why?
|
Animals | 2 | 2023 | 168757 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12959 | 0.010 |
Why?
|
Time Factors | 1 | 2010 | 40075 | 0.010 |
Why?
|
Transcription Factors | 1 | 2018 | 12208 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39050 | 0.010 |
Why?
|